CLAIMS

1. Use of an amount of microparticles in the manufacture of a medicament for treating a kidney neoplasia in a subject in need of, wherein the medicament is to be administered to the kidney neoplasia, and wherein the amount of microparticles delivers a radiation dose between 100 and 600Gy.

2. Use of microparticles in the manufacture of a medicament for the treatment for renal neoplastic conditions in a subject, wherein the microparticles is to be administered to the subject by selective internal radiation therapy (SIRT), and wherein (i) the prescribed activity of the irradiated microparticles used in the SIRT is 0.02 to 3.5 GBq and (ii) the therapy is configured to deliver between 75 and 800 Gy to the site of treatment in the kidney.

3. The use according to claim 1 or claim 2 wherein the microparticles are suitable for selective internal radiation therapy.

4. The use according to claim 1 wherein the microparticles have a level of radioactivity that is between about 0.02 to 3.5 GBq.

5. The use according to claim 4 wherein the radioactivity is capped at a maximum of 3 GBq.

6. The use according to claim 1 or claim 2 wherein radioactivity of the microparticles used in the SIRT is calculated by determining tumour volume and then adjusting an amount of the radioactive microparticles, having regard to tumour volume, to deliver to the kidney neoplasia a radiation dose between 100 and 600Gy.

7. The use according to claim 1 or claim 2 wherein the microparticles are irradiated with yttrium-90.